Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases
Retrieved on:
Monday, March 7, 2022
Science, Cardiology, Biotechnology, Research, Oncology, Health, Mental Health, Clinical Trials, Heart failure, Research, Patient, Pharmacokinetics, Degenerative disease, Epidemiology, A, Death, Quality of life, Neurodegeneration, Cohort, Safety, Blood, FDA, G1, HER4, Cleveland Clinic, Cancer, Salubris Pharmaceuticals, HER3, Clinical trial, Mortality, Center, Drug discovery, Groenewegen, Heart failure with preserved ejection fraction, Northwest Biotherapeutics, Therapy, Pharmaceutical industry, Heart, Heart Failure, JK07, Heart Failure, JK07, HEART FAILURE, JK07
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $32 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.
Key Points:
- Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $32 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd.
- We are focused on advancing our programs and securing additional funding to progress the development of our portfolio of antibody fusion proteins and other complex biologics.
- Since its inception, SalubrisBio has built a drug discovery and development platform to address significant unmet medical needs in cardiovascular diseases, cancer and neurodegenerative diseases.
- SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing complex biologics for cardiovascular, oncology, and neurodegenerative diseases.